Format

Send to

Choose Destination
Vaccine. 2019 Nov 28;37(50):7336-7345. doi: 10.1016/j.vaccine.2017.03.074. Epub 2017 Jun 21.

Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling.

Author information

1
World Health Organization (WHO), Geneva, Switzerland. Electronic address: gottliebs@who.int.
2
World Health Organization (WHO), Geneva, Switzerland.
3
Imperial College, London, UK.
4
Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
5
University of Bristol, UK.
6
University of Washington, Seattle, WA, USA.

Abstract

Development of a vaccine against herpes simplex virus (HSV) is an important goal for global sexual and reproductive health. In order to more precisely define the health and economic burden of HSV infection and the theoretical impact and cost-effectiveness of an HSV vaccine, in 2015 the World Health Organization convened an expert consultation meeting on HSV vaccine impact modelling. The experts reviewed existing model-based estimates and dynamic models of HSV infection to outline critical future modelling needs to inform development of a comprehensive business case and preferred product characteristics for an HSV vaccine. This article summarizes key findings and discussions from the meeting on modelling needs related to HSV burden, costs, and vaccine impact, essential data needs to carry out those models, and important model components and parameters.

KEYWORDS:

HSV vaccines; Herpes simplex virus; Modelling; Sexually transmitted infections

PMID:
28647165
DOI:
10.1016/j.vaccine.2017.03.074
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Spiral, Imperial College Digital Repository
Loading ...
Support Center